{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:01:15Z","timestamp":1790402475914,"version":"4.1.0"},"reference-count":235,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.atherosclerosis.2024.117579","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T12:09:54Z","timestamp":1715774994000},"page":"117579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Advancements in risk stratification and management strategies in primary cardiovascular prevention"],"prefix":"10.1016","volume":"395","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-6895","authenticated-orcid":false,"given":"Fotios","family":"Barkas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf Ziya","family":"Sener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelin Arabacilar","family":"Golforoush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azin","family":"Kheirkhah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rodriguez-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Apellaniz-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph Kwame","family":"Akyea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Bianconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandr","family":"Ceasovschih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying Jie","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariia","family":"Cherska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana Rita","family":"Chora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"D'Oria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadiia","family":"Demikhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duygu","family":"Kocyigit Burunkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Rimbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Macchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnaraj","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasily","family":"Sukhorukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Stoica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Scicali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Storozhenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamol","family":"Uzokov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giovanna","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiel P.C.","family":"van der Vorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentina","family":"Porsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2024.117579_bib1","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American heart association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib2","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM199806043382302","article-title":"Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study","volume":"338","author":"Berenson","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib3","first-page":"586","article-title":"ACC\/AHA guidelines superior to ESC\/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study","volume":"38","author":"Mortensen","year":"2017","journal-title":"Eur. Heart J."},{"issue":"Suppl 2","key":"10.1016\/j.atherosclerosis.2024.117579_bib4","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/heartjnl-2014-305693","article-title":"Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3)","volume":"100","author":"Board","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib6","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib7","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/eurheartj\/ehac056","article-title":"Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm","volume":"43","author":"Hageman","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib8","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib9","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/eurheartj\/ehad161","article-title":"Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction","volume":"44","author":"Nurmohamed","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib11","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/ATVBAHA.123.319932","article-title":"Subclinical atherosclerosis: Part 1: what is it? Can it Be defined at the histological level?","volume":"44","author":"Kawai","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib13","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/01.CIR.89.5.2462","article-title":"A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association","volume":"89","author":"Stary","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib14","doi-asserted-by":"crossref","first-page":"C13","DOI":"10.1016\/j.jacc.2005.10.065","article-title":"Pathology of the vulnerable plaque","volume":"47","author":"Virmani","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib15","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/cvr\/cvac161","article-title":"Integrated single-cell analysis-based classification of vascular mononuclear phagocytes in mouse and human atherosclerosis","volume":"119","author":"Zernecke","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s44161-022-00049-1","article-title":"The why and how of adaptive immune responses in ischemic cardiovascular disease","volume":"1","author":"Mallat","year":"2022","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib17","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.atherosclerosis.2015.05.011","article-title":"Natural progression of atherosclerosis from pathologic intimal thickening to late fibroatheroma in human coronary arteries: a pathology study","volume":"241","author":"Otsuka","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cardiores.2006.09.005","article-title":"Phagocytosis in atherosclerosis: molecular mechanisms and implications for plaque progression and stability","volume":"73","author":"Schrijvers","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/hrt.82.3.265","article-title":"Mechanisms of progression in native coronary artery disease: role of healed plaque disruption","volume":"82","author":"Mann","year":"1999","journal-title":"Heart"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib20","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1136\/hrt.2004.041798","article-title":"Pathologic assessment of the vulnerable human coronary plaque","volume":"90","author":"Kolodgie","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib21","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1161\/01.CIR.94.5.928","article-title":"Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary arteries","volume":"94","author":"Mann","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib22","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","article-title":"Mechanisms of plaque formation and rupture","volume":"114","author":"Bentzon","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib23","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/ATVBAHA.113.302642","article-title":"Has our understanding of calcification in human coronary atherosclerosis progressed?","volume":"34","author":"Otsuka","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCRESAHA.118.311098","article-title":"Reassessing the mechanisms of acute coronary syndromes","volume":"124","author":"Libby","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib25","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.jacc.2013.05.071","article-title":"In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography","volume":"62","author":"Jia","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c1693","article-title":"Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study","volume":"340","author":"Chamnan","year":"2010","journal-title":"Bmj"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib27","article-title":"General health checks in adults for reducing morbidity and mortality from disease","volume":"1","author":"Krogsb\u00f8ll","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042963","article-title":"Evaluation of the uptake and delivery of the NHS Health Check programme in England, using primary care data from 9.5 million people: a cross-sectional study","volume":"10","author":"Patel","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib29","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"collaboration","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib30","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib31","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJM197406062902302","article-title":"The leukocyte count as a predictor of myocardial infarction","volume":"290","author":"Friedman","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib32","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ehj.2004.05.002","article-title":"Associations between differential leucocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30,374 individuals","volume":"25","author":"Wheeler","year":"2004","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib33","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1093\/eurheartj\/ehad649","article-title":"Neutrophil counts and cardiovascular disease","volume":"44","author":"Luo","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2021.106190","article-title":"A review of risk prediction models in cardiovascular disease: conventional approach vs. artificial intelligent approach","volume":"207","author":"Mohd Faizal","year":"2021","journal-title":"Comput. Methods Progr. Biomed."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib35","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jacc.2019.08.012","article-title":"From subclinical atherosclerosis to plaque progression and acute coronary events: JACC state-of-the-art review","volume":"74","author":"Ahmadi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.14336\/AD.2021.0929","article-title":"The functional role of lipoproteins in atherosclerosis: novel directions for diagnosis and targeting therapy","volume":"13","author":"Lu","year":"2022","journal-title":"Aging Dis."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib37","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib38","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMra1806939","article-title":"Lipid management for the prevention of atherosclerotic cardiovascular disease","volume":"381","author":"Michos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib39","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/CIRCULATIONAHA.115.018531","article-title":"Circulating proprotein convertase subtilisin\/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors","volume":"133","author":"Leander","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib40","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/eurheartj\/ehv568","article-title":"Plasma proprotein convertase subtilisin\/kexin type 9 levels and the risk of first cardiovascular events","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib41","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/ATVBAHA.115.306172","article-title":"Association of proprotein convertase subtilisin\/kexin type 9 (PCSK9) with cardiovascular risk in primary prevention","volume":"35","author":"Zhu","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40292-019-00330-8","article-title":"Impact of lipid-lowering therapy on mortality according to the baseline non-HDL cholesterol level: a meta-analysis","volume":"26","author":"Masson","year":"2019","journal-title":"High Blood Pres. Cardiovasc. Prev."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk","volume":"40","author":"Sandesara","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib45","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib46","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5334\/gh.1154","article-title":"World heart federation cholesterol roadmap 2022","volume":"17","author":"Ray","year":"2022","journal-title":"Glob. Heart."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib48","first-page":"2499","article-title":"Lipid-related markers and cardiovascular disease prediction","volume":"307","author":"Emerging Risk Factors","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib49","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.119.041149","article-title":"Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease","volume":"140","author":"Welsh","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib50","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"Bjornson","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib51","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib52","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41569-023-00947-2","article-title":"Lipoprotein(a), platelet function and cardiovascular disease","volume":"21","author":"Bhatia","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib53","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib55","doi-asserted-by":"crossref","first-page":"27229","DOI":"10.1074\/jbc.M703250200","article-title":"Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1\/2-dependent NF-kappaB and C\/EBPbeta activation","volume":"282","author":"Patel","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib56","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.4049\/jimmunol.175.5.3386","article-title":"Regulation of basal and induced expression of C-reactive protein through an overlapping element for OCT-1 and NF-kappaB on the proximal promoter","volume":"175","author":"Voleti","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib57","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/01.ATV.20.9.2094","article-title":"C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis","volume":"20","author":"Torzewski","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib58","doi-asserted-by":"crossref","first-page":"d548","DOI":"10.1136\/bmj.d548","article-title":"C reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data","volume":"342","author":"Wensley","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib59","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib60","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib61","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib62","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib63","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib64","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cell.2019.02.015","article-title":"Genetics of common, complex coronary artery disease","volume":"177","author":"Musunuru","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib65","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia","volume":"16","author":"Berberich","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib66","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/eurheartj\/ehx174","article-title":"A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction","volume":"38","author":"Coassin","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib67","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41569-019-0247-5","article-title":"Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease","volume":"17","author":"Jaiswal","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib68","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s44161-021-00015-3","article-title":"Clonal hematopoiesis in cardiovascular disease and therapeutic implications","volume":"1","author":"Tall","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib69","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib70","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.jacc.2021.09.004","article-title":"Familial hypercholesterolemia: JACC focus seminar 4\/4","volume":"78","author":"Brandts","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12111065","article-title":"Familial hypercholesterolemia and lipoprotein(a): a gordian knot in cardiovascular prevention","volume":"12","author":"Koutsogianni","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2024.02.031","article-title":"Exploring the landscape of familial hypercholesterolemia: unraveling genetic complexity and clinical implications","author":"Barkas","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib73","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamacardio.2019.5954","article-title":"Association of monogenic vs polygenic hypercholesterolemia with risk of atherosclerotic cardiovascular disease","volume":"5","author":"Trinder","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib74","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2013.12.028","article-title":"Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia","volume":"233","author":"Santos","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib75","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib76","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/jama.2020.5685","article-title":"Lipids and lipoproteins in 2020","volume":"324","author":"Ference","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib77","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib78","first-page":"1241","article-title":"A decade of genome-wide association studies for coronary artery disease: the challenges ahead","volume":"114","author":"Erdmann","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib79","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jacc.2018.07.079","article-title":"Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention","volume":"72","author":"Inouye","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib80","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41569-021-00638-w","article-title":"Clinical utility of polygenic risk scores for coronary artery disease","volume":"19","author":"Klarin","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib81","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-018-0183-z","article-title":"Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations","volume":"50","author":"Khera","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib82","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/CIRCULATIONAHA.116.024436","article-title":"Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting","volume":"135","author":"Natarajan","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib83","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1038\/s41467-020-17374-3","article-title":"Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions","volume":"11","author":"Fahed","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib84","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.120.003304","article-title":"Integrated polygenic tool substantially enhances coronary artery disease prediction","volume":"14","author":"Riveros-Mckay","year":"2021","journal-title":"Circ. Genom. Precis. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib85","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1605086","article-title":"Genetic risk, adherence to a healthy lifestyle, and coronary disease","volume":"375","author":"Khera","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib86","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/j.jacc.2020.04.027","article-title":"Limitations of contemporary guidelines for managing patients at high genetic risk of coronary artery disease","volume":"75","author":"Aragam","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib87","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2020.12.021","article-title":"Vascular imaging of atherosclerosis: strengths and weaknesses","volume":"319","author":"Mantella","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib89","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jcct.2022.07.002","volume":"16","author":"Cury","year":"2022","journal-title":"J. Cardiovasc. Comput. Tomogr."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib93","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jacc.2018.05.027","article-title":"Coronary calcium score and cardiovascular risk","volume":"72","author":"Greenland","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib215","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/heartjnl-2011-300747","article-title":"Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review","volume":"98","author":"Peters","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib216","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.jcmg.2022.03.031","article-title":"The prognostic value of CAC zero among individuals presenting with chest pain: a meta-analysis","volume":"15","author":"Agha","year":"2022","journal-title":"JACC Cardiovasc. Imag."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib217","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2012.9624","article-title":"Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals","volume":"308","author":"Yeboah","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib218","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jama.2018.4242","article-title":"Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US preventive services task force","volume":"320","author":"Lin","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib219","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/CIRCULATIONAHA.116.026964","article-title":"Prevalence of subclinical coronary artery disease in masters endurance athletes with a low atherosclerotic risk profile","volume":"136","author":"Merghani","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib90","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/ehjci\/jeu188","article-title":"Atherosclerotic plaque characterization by CT angiography for identification of high-risk coronary artery lesions: a comparison to optical coherence tomography","volume":"16","author":"Nakazato","year":"2015","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib99","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/HCO.0000000000000917","article-title":"Coronary plaque features on CTA can identify patients at increased risk of cardiovascular events","volume":"36","author":"Andreini","year":"2021","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib220","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jcmg.2008.11.015","article-title":"Prognostic value of coronary computed tomographic angiography for prediction of cardiac events in patients with suspected coronary artery disease","volume":"2","author":"Hadamitzky","year":"2009","journal-title":"JACC Cardiovasc. Imag."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib221","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jcmg.2019.06.019","article-title":"Coronary plaque features on CTA can identify patients at increased risk of cardiovascular events","volume":"13","author":"Andreini","year":"2020","journal-title":"JACC Cardiovasc. Imag."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib222","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCIMAGING.113.001047","article-title":"Prognostic value of nonobstructive and obstructive coronary artery disease detected by coronary computed tomography angiography to identify cardiovascular events","volume":"7","author":"Bittencourt","year":"2014","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib223","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jcmg.2012.03.019","article-title":"The napkin-ring sign indicates advanced atherosclerotic lesions in coronary CT angiography","volume":"5","author":"Maurovich-Horvat","year":"2012","journal-title":"JACC Cardiovasc. Imag."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib100","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.21037\/atm-2020-cass-16","article-title":"Magnetic resonance imaging of carotid plaques: current status and clinical perspectives","volume":"8","author":"Kassem","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib224","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.15557\/JoU.2020.0022","article-title":"Ultrasonography of vulnerable atherosclerotic plaque in the carotid arteries: B-mode imaging","volume":"20","author":"Fedak","year":"2020","journal-title":"J. Ultrason."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib102","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.jacc.2022.03.352","article-title":"Arterial ultrasound testing to predict atherosclerotic cardiovascular events","volume":"79","author":"Nicolaides","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib225","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jacc.2017.05.033","article-title":"Subclinical atherosclerosis burden by 3D ultrasound in mid-life: the PESA study","volume":"70","author":"Lopez-Melgar","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib226","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jacc.2015.12.056","article-title":"Femoral and carotid subclinical atherosclerosis association with risk factors and coronary calcium: the AWHS study","volume":"67","author":"Laclaustra","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib107","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/eurheartj\/ehq280","article-title":"Imaging of coronary atherosclerosis: intravascular ultrasound","volume":"31","author":"Garcia-Garcia","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib108","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/eurheartj\/ehp433","article-title":"Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis","volume":"31","author":"Prati","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib88","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jacc.2018.12.054","article-title":"Artificial intelligence in cardiovascular imaging: JACC state-of-the-art review","volume":"73","author":"Dey","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib91","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2018.10.066","article-title":"Coronary artery plaque characteristics associated with adverse outcomes in the SCOT-heart study","volume":"73","author":"Williams","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib92","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1161\/CIRCULATIONAHA.119.044720","article-title":"Low-attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction: results from the multicenter SCOT-heart trial (scottish computed tomography of the HEART)","volume":"141","author":"Williams","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib94","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.atherosclerosis.2015.05.021","article-title":"Statins and the coronary plaque calcium \"paradox\": insights from non-invasive and invasive imaging","volume":"241","author":"Ferencik","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib95","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jcmg.2023.10.004","article-title":"Coronary stenosis quantification with ultra-high-resolution photon-counting detector CT angiography: comparison with 3D quantitative coronary angiography","volume":"17","author":"Eberhard","year":"2024","journal-title":"JACC Cardiovasc. Imag."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib96","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jcmg.2015.08.004","article-title":"Multimodality imaging in the context of transcatheter mitral valve replacement: establishing consensus among modalities and disciplines","volume":"8","author":"Blanke","year":"2015","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib97","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamacardio.2017.4973","article-title":"Use of high-risk coronary atherosclerotic plaque detection for risk stratification of patients with stable chest pain: a secondary analysis of the promise randomized clinical trial","volume":"3","author":"Ferencik","year":"2018","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib98","first-page":"521","article-title":"Lesion-specific and vessel-related determinants of fractional flow reserve beyond coronary artery stenosis, JACC","volume":"11","author":"Ahmadi","year":"2018","journal-title":"Cardiovasc. Imaging"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib101","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.numecd.2023.04.019","article-title":"A new score for improving cardiovascular risk prediction and prevention","volume":"33","author":"Del Giorno","year":"2023","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib103","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.300.2.197","article-title":"Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis","volume":"300","author":"Ankle Brachial Index","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib104","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jacc.2013.09.063","article-title":"Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects","volume":"63","author":"Ben-Shlomo","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib105","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1093\/eurheartj\/ehz350","article-title":"Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans","volume":"40","author":"Thijssen","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib106","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1161\/ATVBAHA.120.313130","article-title":"Uses of arterial stiffness in clinical practice","volume":"40","author":"Wilkinson","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib227","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1161\/CIR.0b013e318276fbcb","article-title":"Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association","volume":"126","author":"Aboyans","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib228","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13047-019-0350-1","article-title":"The reliability of the ankle brachial index: a systematic review","volume":"12","author":"Casey","year":"2019","journal-title":"J. Foot Ankle Res."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib229","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejvs.2010.09.020","article-title":"Use and utility of ankle brachial index in patients with diabetes","volume":"41","author":"Potier","year":"2011","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib230","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/cvr\/cvac095","article-title":"Flow-mediated dilation reference values for evaluation of endothelial function and cardiovascular health","volume":"119","author":"Heiss","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib231","doi-asserted-by":"crossref","DOI":"10.3791\/52070-v","article-title":"Ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery in clinical research","author":"Alley","year":"2014","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib232","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/ATVBAHA.119.313132","article-title":"How to measure arterial stiffness in humans","volume":"40","author":"Segers","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib233","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12248","article-title":"The relationship between renal resistive index, arterial stiffness, and atherosclerotic burden: the link between macrocirculation and microcirculation","volume":"16","author":"Calabia","year":"2014","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib234","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jch.13819","article-title":"Prognostic significance of the renal resistive index in the primary prevention of type II diabetes","volume":"22","author":"Delsart","year":"2020","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib235","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13101687","article-title":"Current insights into the significance of the renal resistive index in kidney and cardiovascular disease","volume":"13","author":"Darabont","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib109","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jcmg.2011.03.020","article-title":"Intravascular optical imaging technology for investigating the coronary artery","volume":"4","author":"Suter","year":"2011","journal-title":"JACC Cardiovasc. Imag."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib110","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01456-3","article-title":"Machine learning models for screening carotid atherosclerosis in asymptomatic adults","volume":"11","author":"Yu","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213653","article-title":"Cardiovascular disease risk prediction using automated machine learning: a prospective study of 423,604 UK Biobank participants","volume":"14","author":"Alaa","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib112","series-title":"Best Practices for Heart Disease and Stroke: A Guide to Effective Approaches and Strategies","author":"Prevention","year":"2022"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272846","article-title":"Towards effective clinical decision support systems: a systematic review","volume":"17","author":"Hak","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib114","doi-asserted-by":"crossref","first-page":"74","DOI":"10.14744\/AnatolJCardiol.2023.3685","article-title":"Artificial intelligence-based clinical decision support systems in cardiovascular diseases","volume":"28","author":"Bozyel","year":"2024","journal-title":"Anatol. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib115","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s43588-022-00199-z","article-title":"Network cartographs for interpretable visualizations","volume":"2","author":"Hutter","year":"2022","journal-title":"Nat. Comput. Sci."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib116","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/s41467-021-22570-w","article-title":"The VRNetzer platform enables interactive network analysis in Virtual Reality","volume":"12","author":"Pirch","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib117","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1038\/s41467-021-26674-1","article-title":"Network analysis reveals rare disease signatures across multiple levels of biological organization","volume":"12","author":"Buphamalai","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib118","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg6375","article-title":"AutoCore: a network-based definition of the core module of human autoimmunity and autoinflammation","volume":"9","author":"Guthrie","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib119","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/joim.13333","article-title":"The Mediterranean diet and health: a comprehensive overview","volume":"290","author":"Guasch-Ferre","year":"2021","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib120","first-page":"e563","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib121","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41569-018-0004-1","article-title":"Role of salt intake in prevention of cardiovascular disease: controversies and challenges","volume":"15","author":"He","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib122","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/obr.12433","article-title":"Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis","volume":"17","author":"Zomer","year":"2016","journal-title":"Obes. Rev."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib123","article-title":"Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis","volume":"359","author":"Ma","year":"2017","journal-title":"Bmj"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib124","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jcmg.2020.10.019","article-title":"High-risk coronary plaque regression after intensive lifestyle intervention in nonobstructive coronary disease: a randomized study","volume":"14","author":"Henzel","year":"2021","journal-title":"JACC Cardiovasc. Imag."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib125","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1001\/jama.280.23.2001","article-title":"Intensive lifestyle changes for reversal of coronary heart disease","volume":"280","author":"Ornish","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib126","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.21037\/cdt.2017.03.20","article-title":"The role of nutraceuticals in the prevention of cardiovascular disease","volume":"7","author":"Sosnowska","year":"2017","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib127","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20020351","article-title":"Polyphenol health effects on cardiovascular and neurodegenerative disorders: a review and meta-analysis","volume":"20","author":"Poti","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib128","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.atherosclerosis.2013.11.043","article-title":"Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease","volume":"232","author":"Gylling","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib129","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.3390\/nu5103779","article-title":"Polyphenols: benefits to the cardiovascular system in health and in aging","volume":"5","author":"Khurana","year":"2013","journal-title":"Nutrients"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib130","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3945\/ajcn.113.082024","article-title":"Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials","volume":"99","author":"Liu","year":"2014","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib131","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clnu.2014.03.009","article-title":"Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials","volume":"34","author":"Liu","year":"2015","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib132","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib133","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/CIRCULATIONAHA.110.010710","article-title":"Dose response between physical activity and risk of coronary heart disease: a meta-analysis","volume":"124","author":"Sattelmair","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib134","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1249\/MSS.0000000000001939","article-title":"Physical activity, all-cause and cardiovascular mortality, and cardiovascular disease","volume":"51","author":"Kraus","year":"2019","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/eurheartj\/ehaa605","article-title":"2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease","volume":"42","author":"Pelliccia","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib136","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12471-021-01642-y","article-title":"Lifestyle management to prevent atherosclerotic cardiovascular disease: evidence and challenges","volume":"30","author":"van Trier","year":"2022","journal-title":"Neth. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib137","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1161\/CIRCULATIONAHA.109.891523","article-title":"Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes","volume":"121","author":"Chow","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib138","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.879726","article-title":"Electronic cigarette use and the risk of cardiovascular diseases","volume":"9","author":"Espinoza-Derout","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib139","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006353","article-title":"Impact of electronic cigarettes on the cardiovascular system","volume":"6","author":"Qasim","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib140","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib141","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib142","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/eurheartj\/ehab742","article-title":"The 'ten commandments' for the 2021 ESC Guidelines on CVD prevention","volume":"43","author":"Carballo","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib143","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","article-title":"A systematic review and meta-analysis on the therapeutic equivalence of statins","volume":"35","author":"Weng","year":"2010","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib144","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jacc.2021.10.035","article-title":"Coronary atherosclerotic plaque regression: JACC state-of-the-art review","volume":"79","author":"Dawson","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib145","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib146","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib147","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib148","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11883-024-01188-5","article-title":"How will our practice change after the CLEAR outcomes trial?","volume":"26","author":"Abrahams","year":"2024","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib149","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jacl.2023.02.002","article-title":"Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: a secondary analysis of the CLEAR harmony trial","volume":"17","author":"Ridker","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib150","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib151","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib152","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib153","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib154","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117504","article-title":"Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: a PACMAN-AMI randomized clinical trial substudy","volume":"392","author":"Rexhaj","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib156","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc. Imag."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib157","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/13543784.2023.2267972","article-title":"MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment","volume":"32","author":"Burnett","year":"2023","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib158","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S2213-8587(23)00325-X","article-title":"PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial","volume":"12","author":"Koren","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib159","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12010070","article-title":"Gene therapy targeting PCSK9","volume":"12","author":"Katzmann","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib160","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/d41586-023-03543-z","article-title":"First trial of 'base editing' in humans lowers cholesterol - but raises safety concerns","volume":"623","author":"Naddaf","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib161","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/ATVBAHA.122.317963","article-title":"New approaches for targeting PCSK9: small-interfering ribonucleic acid and genome editing","volume":"43","author":"Oostveen","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib162","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s11883-023-01175-2","article-title":"How to handle elevated triglycerides: life after PROMINENT","volume":"25","author":"Pirillo","year":"2023","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib163","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib164","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib165","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib166","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006981","article-title":"Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: a randomized clinical trial","volume":"6","author":"Alfaddagh","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib167","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.atherosclerosis.2019.04.213","article-title":"An omega-3 fatty acid plasma index >\/=4% prevents progression of coronary artery plaque in patients with coronary artery disease on statin treatment","volume":"285","author":"Alfaddagh","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib168","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib169","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015593","article-title":"Effects of fatty acid therapy in addition to strong statin on coronary plaques in acute coronary syndrome: an optical coherence tomography study","volume":"9","author":"Kita","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib170","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jjcc.2017.07.007","article-title":"A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins","volume":"70","author":"Watanabe","year":"2017","journal-title":"J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib171","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib172","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/HJH.0000000000000614","article-title":"Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"J. Hypertens."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib173","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1097\/HJH.0000000000001547","article-title":"Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials","volume":"35","author":"Thomopoulos","year":"2017","journal-title":"J. Hypertens."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib174","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial","volume":"292","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib175","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(20)30038-3","article-title":"Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials","volume":"8","author":"Ghosh-Swaby","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib176","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7326\/M20-0864","article-title":"Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis","volume":"173","author":"Tsapas","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib177","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jacc.2017.07.001","article-title":"Primary prevention of cardiovascular disease in diabetes mellitus","volume":"70","author":"Newman","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib178","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1007\/s00125-021-05529-w","article-title":"The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials","volume":"64","author":"Lin","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib179","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.4239\/wjd.v12.i11.1856","article-title":"Effect of glycemic control on markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus: a review","volume":"12","author":"Antoniou","year":"2021","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib180","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib181","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S2213-8587(17)30194-8","article-title":"Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial","volume":"5","author":"Petrie","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib182","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1507\/endocrj.EJ18-0022","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION)","volume":"65","author":"Nomiyama","year":"2018","journal-title":"Endocr. J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib183","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/ehjcvp\/pvac059","article-title":"Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial","volume":"9","author":"Tanaka","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib184","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12933-020-01079-4","article-title":"Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study","volume":"19","author":"Katakami","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib185","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12933-017-0564-0","article-title":"Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study","volume":"16","author":"Shigiyama","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib186","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12933-019-0839-8","article-title":"How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial","volume":"18","author":"Bosch","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib187","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib188","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1161\/CIRCULATIONAHA.117.029529","article-title":"Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus","volume":"136","author":"Striepe","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib189","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030578","article-title":"Sodium-glucose cotransporter-2 inhibitors and primary prevention of atherosclerotic cardiovascular disease: a meta-analysis of randomized trials and systematic review","volume":"12","author":"Rahman","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib190","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib191","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib192","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib193","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib194","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib195","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib196","unstructured":"EMA), EMA, Wegovy, In."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib197","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40265-023-01992-4","article-title":"Tirzepatide: a review in type 2 diabetes","volume":"84","author":"France","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib198","doi-asserted-by":"crossref","first-page":"213","DOI":"10.12997\/jla.2023.12.3.213","article-title":"The cardiovascular effect of tirzepatide: a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist","volume":"12","author":"Cho","year":"2023","journal-title":"J. Lipid. Atheroscler."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib199","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib200","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2019.03.501","article-title":"Aspirin for primary prevention of cardiovascular events","volume":"73","author":"Abdelaziz","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib201","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib202","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurheartj\/ehy813","article-title":"Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials","volume":"40","author":"Mahmoud","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib203","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib204","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib205","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib206","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","article-title":"Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study","volume":"11","author":"Vaidya","year":"2018","journal-title":"JACC Cardiovasc. Imag."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib207","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib208","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib209","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-Driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial","volume":"7","author":"Svensson","year":"2022","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib210","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","article-title":"From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?","volume":"117","author":"Ridker","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib211","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jacc.2021.12.016","article-title":"Managing atherosclerotic cardiovascular risk in young adults: JACC state-of-the-art review","volume":"79","author":"Stone","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib212","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.jacc.2023.09.817","article-title":"Primary prevention of subclinical atherosclerosis in young adults: JACC review topic of the week","volume":"82","author":"Devesa","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib213","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.jacc.2023.09.814","article-title":"Determinants of progression and regression of subclinical atherosclerosis over 6 years","volume":"82","author":"Mendieta","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2024.117579_bib214","first-page":"2463","article-title":"Predicting subclinical atherosclerosis in low-risk individuals: ideal cardiovascular health score and fuster-BEWAT score","volume":"70","author":"Fernandez-Alvira","year":"2017","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024001394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024001394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T17:03:56Z","timestamp":1726247036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915024001394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":235,"alternative-id":["S0021915024001394"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117579","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements in risk stratification and management strategies in primary cardiovascular prevention","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117579"}}